Clinical Trial Update: A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors [Phase 1]

View source ↗

Summary

The update reports that the Phase 1 study of AK112, a PD-1/VEGF bispecific antibody, in patients with advanced solid tumors has completed; results are not detai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Akesobio Australia Pty Ltd | Conditions: Neoplasms Malignant | Phase 1 | Status: COMPLETED